# A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer

> **NCT05963997** · PHASE1,PHASE2 · COMPLETED · sponsor: **Carrick Therapeutics Limited** · enrollment: 49 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Locally Advanced Breast Cancer
- Breast Cancer

## Interventions

- **DRUG:** Samuraciclib
- **DRUG:** Elacestrant Dihydrochloride

## Key facts

- **NCT ID:** NCT05963997
- **Lead sponsor:** Carrick Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-09
- **Primary completion:** 2026-03-06
- **Final completion:** 2026-03-06
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05963997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05963997, "A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05963997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*